ACU Reports 50% EPS Beat in Q2 2026 Driven by MyMedic Acquisition and Margin Expansion

• Acme United reported a 50.62% EPS beat in Q2 2026, reaching $1.22 against estimates of $0.81, while revenue grew 16% to $62.7 million.
• The outperformance was primarily fueled by the MyMedic acquisition, which drove organic growth of 8% and expanded gross margins to 42.6%.
• Management anticipates continued margin recovery as the company transitions to lower-cost inventory, though elevated SG&A and geographic headwinds remain key risks.

Acme United Corporation (ACU) delivered a robust second-quarter 2026 performance, significantly exceeding Wall Street expectations across both earnings and revenue metrics. Diluted earnings per share reached $1.22, marking a 50.62% surprise against consensus estimates of $0.81 . Revenue climbed 16% year-over-year to $62.7 million, surpassing forecasts of $58.1 million by nearly 8% .

The stock reacted swiftly to the results, surging approximately 11.92% to 17.52% following the release, and nearing its 52-week high of $51.88 . This market response underscores investor appetite for the company's margin expansion and successful integration strategies. The strong finish positions the company favorably as it moves into the fourth quarter.

How Did the MyMedic Acquisition Drive Revenue Growth?

The primary catalyst for Acme United's Q2 2026 top-line expansion was the acquisition of MyMedic, which contributed significantly to the 16% year-over-year sales increase . Excluding the impact of this acquisition, the company still achieved an 8% organic growth rate, indicating underlying strength in its core operations . This dual growth driver highlights both the immediate impact of strategic acquisitions and the resilience of existing business lines.

Management is actively integrating MyMedic into the broader corporate structure, with a strategic pivot away from direct-to-consumer channels toward mass retail expansion . This shift aims to leverage larger distribution networks and increase brand visibility in broader markets. The integration is progressing as planned, with leadership expressing confidence in the long-term synergies this acquisition will provide.

What Factors Are Supporting Margin Recovery?

Gross margins expanded to 42.6% in Q2 2026, up from 41.0% in the prior year period, signaling effective cost management despite broader inflationary pressures . CEO Johnsen highlighted that this margin recovery is expected to continue as the company replaces higher-tariff inventory with lower-cost stock . This transition is anticipated to be largely complete by the end of the year, providing significant tailwinds for profitability in subsequent quarters .

The company's ability to navigate tariff-related cost pressures through inventory optimization has been a critical factor in its operational efficiency. By strategically managing its supply chain, Acme United has mitigated some of the headwinds associated with global trade tensions. This proactive approach to cost management is expected to drive strong Q4 profitability, supported by seasonal demand for medical safety products .

What Are the Key Risks and Headwinds?

Despite the positive results, investors should monitor several key risks that could impact future performance. Selling, general, and administrative (SG&A) expenses remain elevated at 32% of sales, potentially compressing net income margins . This high expense ratio suggests that the company is incurring significant costs to support its growth initiatives and integration efforts.

Other headwinds include ongoing volatility in tariff and freight costs, potential currency fluctuations, and uneven geographic performance . Canada, in particular, is currently lagging behind other regions, which may dampen overall growth prospects . Investors should remain cautious of these factors as they evaluate the company's long-term trajectory and the sustainability of its recent earnings beat.

The combination of strong earnings, margin expansion, and strategic acquisitions positions Acme United for continued growth. However, the elevated SG&A and geographic disparities require close monitoring to ensure that profitability remains on an upward trajectory. The company's ability to execute its margin recovery plan and integrate MyMedic successfully will be critical in the coming quarters.